Unlocking the Missing Puzzle Piece in Cancer Real-World Data
Value Proposition for Life Science Companies
- What products are being used and how
- Differences between therapies in terms of patient tolerance
- Reasons for switching and discontinuations
- How drugs are used in the real-world vs. trials (drive label expansion via additional trials)
- Dose, frequency
- Usage in other cancer types
- Concordance between real-world data vs. Phase 3 clinical trial data
- Track longitudinal outcomes data
- Show value across different indications
Building the Largest Real-World Cancer Patient Experience Database
Carevive OPT-IN® – The Oncology Pragmatic Trial Investigator Network
Funded by a growing list of life science companies, Carevive OPT-IN® is a novel and unique real-world patient experience dataset consisting of EHR-derived clinical data and longitudinal patient-reported outcomes (PRO). Together, this combination presents the most comprehensive picture of real-world symptoms of disease and treatment in cancer.
Life science companies can license these data to:
- Support drug development, commercial, and market access efforts with novel evidence and insights including how and when therapies are being used in the real-world setting, differences between trial results and real-world data and longitudinal patient experience
- Conduct bespoke research in collaboration with Carevive OPT-IN® sites and their patients
- Become Carevive design-partners in other cancer types
Tumor registries to be initiated in 2020-2022
Myeloma
LIVE
Chronic Lymphocytic Leukemia
Renal Cell Carcinoma
Breast Cancer
LIVE
DLBCL
Follicular Lymphoma
Urothelial
Lung Cancer
LIVE
Ovarian Cancer
LIVE
Hepatocellular Carcinoma
Prostate Cancer
AML
Stomach Cancer
Colorectal Carcinoma
Pancreatic Cancer
Head and Neck
0
Total US 2019 Analytic Cases
0
Carevive OPT-IN® Network Analytic Cases
0
%
Share of Total Cancer Market
OPT-imizing Patient Experience Data
